Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects

This is a randomized, double‐blind, placebo‐controlled, single ascending dose Phase 1study designed to evaluate the safety, tolerability, pharmacokinetic (PK), andpharmacodynamic (PD) profiles of MWX203 Injection in healthy Chinese subjects.The study comprises six dose cohorts with a planned enrollment of 54 subjects. Theprimary endpoint is safety, assessed by adverse events (AEs), serious adverse events(SAEs), vital signs, physical examinations, laboratory tests, and 12‐leadelectrocardiograms. Secondary endpoints include plasma PK parameters, urinary PKparameters, and immunogenicity (anti‐drug antibodies).